Caris Life Sciences (CAI) closed at $25.23 on November 6, 2026, down 3.1% from the previous close, on volume of 9,775,948 shares (30-day average 3,552,257).
Data as of November 6, 2026.
6-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 2, 2026 | Call Spread | 15-Jan-2730 : 35 C | 2,800 |
| 2-2 | The next 1 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 6, 2026. See the 10 largest for 30, 60 and 90 days
TipRanks (Fri, 6-Nov 8:51 AM ET)
TipRanks (Thu, 5-Nov 5:51 PM ET)
TipRanks (Thu, 5-Nov 5:46 PM ET)
Piper Sandler Remains a Hold on Caris Life Sciences, Inc. (CAI)
TipRanks (Thu, 5-Nov 9:28 AM ET)
TipRanks (Thu, 5-Nov 7:40 AM ET)
Goldman Sachs Sticks to Its Buy Rating for Caris Life Sciences, Inc. (CAI)
TipRanks (Thu, 5-Nov 7:40 AM ET)
At a glance: stocks gapping down premarket
Seeking Alpha News (Thu, 5-Nov 7:34 AM ET)
Caris Life Sciences, Inc. GAAP EPS of $0.05 beats by $0.02, revenue of $275.4M beats by $20.06M
Seeking Alpha News (Wed, 4-Nov 4:38 PM ET)
Caris Life Sciences Reports Third Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
PRNewswire (Wed, 4-Nov 4:05 PM ET)
Caris Life Sciences, Inc. Q3 2026 Earnings Preview
Seeking Alpha News (Wed, 4-Nov 9:46 AM ET)
Caris Life Sciences Inc is a patient-centric, next-generation AI TechBio company. It develop and commercialize solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale.
Caris Life Sciences trades on the NASDAQ stock market under the symbol CAI.
As of November 6, 2026, CAI stock price declined to $25.23 with 9,775,948 million shares trading.
CAI has a beta of 2.46, meaning it tends to be more sensitive to market movements. CAI has a correlation of 0.16 to the broad based SPY ETF.
CAI has a market cap of $7.24 billion. This is considered a Mid Cap stock.
Last quarter Caris Life Sciences reported $275 million in Revenue and $.05 earnings per share. This beat revenue expectation by $21 million and exceeded earnings estimates by $.03.
The top ETF exchange traded funds that CAI belongs to (by Net Assets): VTI, VB, VBK, VXF, IBB.
CAI has underperformed the market in the last year with a price return of +2.5% while the SPY ETF gained +10.8%. However, in the short term, CAI had mixed performance relative to the market. It has outperformed in the last 3 months, returning +26.2% vs -4.1% return in SPY. But in the last 2 weeks, CAI shares have been beat by the market, returning -21.2% compared to an SPY return of -3.2%.
CAI support price is $24.74 and resistance is $27.32 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CAI shares will trade within this expected range on the day.
